Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Diego, California
- Most recent report
- 10-Q, filed Nov 2, 2026
- Incorporated
- California
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 1438533
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 49
News 8 of 153
Prospectuses and Registrations 8 of 35
- S-8 Registration statement for an employee plan Jun 17, 2026
- 424B5 Prospectus supplement for an offering May 7, 2026
- FWP Free writing prospectus May 7, 2026
- 424B5 Prospectus supplement for an offering May 5, 2026
- S-8 Registration statement for an employee plan Jun 17, 2025
- 424B5 Prospectus supplement for an offering Nov 8, 2024
- 424B5 Prospectus supplement for an offering Nov 7, 2024
- 424B5 Prospectus supplement for an offering Oct 31, 2024
Proxies 8 of 15
- DEFA14A Extra proxy material Apr 6, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 6, 2026
- DEFA14A Extra proxy material Apr 1, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 1, 2025
- DEFA14A Extra proxy material Mar 27, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 13, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 4, 2022
Ownership 8 of 717
- SCHEDULE 13G/A Large holder reported a passive stake, amended Nov 5, 2026
- 4 Insider reported a trade Oct 19, 2026
- 144 Notice of a proposed sale of restricted stock Oct 15, 2026
- 4 Insider reported a trade Sep 17, 2026
- 4 Insider reported a trade Sep 17, 2026
- 4 Insider reported a trade Sep 17, 2026
- 4 Insider reported a trade Sep 17, 2026
- 4 Insider reported a trade Sep 17, 2026
Other 8 of 31
Everything here comes from Travere Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.